Acrivon Advances Key Clinical Trials with $90M Cash Runway into 2027
Event summary
- Acrivon expects interim Phase 2b data for ACR-368 in serous endometrial cancer by H2 2026
- ACR-2316 enters randomized dose expansion phase with durable single-agent activity observed
- $90M cash position projected to fund operations into Q4 2027
- Net loss narrowed to $18.0M in Q2 2026 from $21.0M in Q2 2025
The big picture
Acrivon's progress reflects the growing emphasis on precision oncology, where proprietary platforms like AP3 are enabling more targeted drug development. The company's ability to demonstrate durable single-agent activity with ACR-2316 in difficult-to-treat cancers positions it competitively in the crowded kinase inhibitor space. With a clear runway into 2027, Acrivon now faces the critical test of converting clinical data into regulatory and commercial success.
What we're watching
- Clinical Validation
- Whether ACR-368's Phase 2b interim data will support accelerated regulatory pathway in endometrial cancer
- Pipeline Progression
- The pace at which Acrivon advances its CDK11 inhibitor program into IND-enabling studies
- Financial Sustainability
- How Acrivon will allocate remaining $90M runway to support multiple clinical programs through 2027
Related topics